BioTerm

Pharmaceuticals Ltd.

Preventerm

Preventerm inhibits three molecules that block contractions. The medication acts to prevent premature labor whatever the cause, be it infection, inflammation, bleeding, an overextended uterus, or too much amniotic fluid. Every day that a premature baby manages to stay in the womb increases their chances of survival, and a normal healthy life once they are born.

Premature birth is the leading cause of infant death in developed countries. It also accounts for half of all neurological handicaps in newborns, such as cerebral palsy, blindness, and developmental defects. Babies born at 22 weeks have a 10-15% survival rate. Those born just five weeks later have a 90% survival rate.

 While more than one tenth of all births in the U.S. are delivered prematurely, until now there has been no failsafe measure to prevent it from happening

The treatments practiced today attempt to prevent preterm birth are unsatisfactory. They include intravenous fluids and bed rest, tocolytic agents, such as uterine contraction inhibiting agents and surgical procedures that attempt to strengthen the cervix. In the worst-case scenarios, mothers taking a preterm labor drug may suffer a respiratory arrest and die. In the best-case scenarios, the delivery can be postponed for a few extra days.

Preventerm inhibits three molecules – including prostaglandins which are involved in pre-term birth – that block contractions. The medication acts to prevent premature labor whatever the cause, be it infection, inflammation, bleeding, an overextended uterus, or too much amniotic fluid.

Preventerm is based on a collagen inhibitor central to cervical flexibility. It can be administered vaginally from the second trimester up until birth, and it inhibits the final common pathways for triggering preterm birth, therefore effective regardless of the cause for labor.

              

Various scientific case reports on the use of the Preventerm source molecule report no adverse side effects to the mother or infant


Initial tests of Preventerm have shown a 90% efficacy rate in preventing preterm labor – overwhelmingly more effective than any of the currently available treatment modalities


Preventerm stands to decrease the overall expense of preterm infant health care and will reduce infant mortality as well as post-natal complications considerably


We intend to generate revenue through joint and/or strategic collaborations with large pharmaceutical and biotechnology companies in order to further develop our products, jointly facilitate regulatory approval, and subsequently to bring our products to the global markets


A unique investment opportunity: Patented and patent-pending breakthrough drugs Direct solution to a pressing market need Vast expertise in the OB/Gyn industry Several discrete multi-billion dollar markets Strategic value to large pharmaceutical companies

Log-in

 Name

 

Email

 LOG-IN